Kaposi's sarcoma-associated herpesvirus: the role of lytic replication in targeted therapy

被引:15
作者
Andrei, Graciela [1 ]
Snoeck, Robert [1 ]
机构
[1] Katholieke Univ Leuven, Rega Inst Med Res, Virol Lab, Leuven, Belgium
关键词
antivirals; human herpesvirus-8; Kaposi sarcoma; Kaposi's sarcoma-associated herpesvirus; lytic induction therapy; molecular-targeted therapy; PRIMARY EFFUSION LYMPHOMA; MULTICENTRIC CASTLEMANS-DISEASE; HIV-INFECTED PATIENTS; RECONSTITUTION INFLAMMATORY SYNDROME; HUMAN CYTOMEGALOVIRUS PROTEASE; AIDS MALIGNANCY CONSORTIUM; EPSTEIN-BARR-VIRUS; PHASE-II TRIAL; ANTIVIRAL ACTIVITY; ANTIRETROVIRAL THERAPY;
D O I
10.1097/QCO.0000000000000213
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose of reviewTo discuss the role of Kaposi's sarcoma-associated herpesvirus (KSHV) lytic replication in viral-associated diseases and assess the progress on targeting KSHV lytic replication as a strategy to prevent KSHV-related malignancies.Recent findingsNew inhibitors of viral lytic replication are being developed as well as novel modalities are being investigated to target cellular processes that the virus hijacks during its life cycle. Research has also focused on reactivating viral lytic replication in latently infected tumour cells (lytic induction therapy) to promote death of tumour cells.SummaryKSHV is linked to three malignancies: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Despite significant progress in understanding KSHV pathobiology, no therapeutic guidelines for the management of KSHV-related diseases exist, and current treatments are suboptimal and associated with toxicity. Antiherpesvirus drugs have shown inconsistent results in KSHV-associated malignancies that harbour the virus in a latent state. However, lytic replication plays a crucial role in the process of tumorigenesis. Therefore, not only antiviral agents directed against the virus replicative cycle but also agents that target cellular processes that are activated by the virus are being investigated. Antivirals may also be used in combination with inducers of the viral lytic stage.
引用
收藏
页码:611 / 624
页数:14
相关论文
共 125 条
[1]   Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases [J].
Ablashi, DV ;
Chatlynne, LG ;
Whitman, JE ;
Cesarman, E .
CLINICAL MICROBIOLOGY REVIEWS, 2002, 15 (03) :439-+
[2]   Paradoxical Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients Treated With Combination Antiretroviral Therapy After AIDS-Defining Opportunistic Infection [J].
Achenbach, Chad J. ;
Harrington, Robert D. ;
Dhanireddy, Shireesha ;
Crane, Heidi M. ;
Casper, Corey ;
Kitahata, Mari M. .
CLINICAL INFECTIOUS DISEASES, 2012, 54 (03) :424-433
[3]   Productively Infected Murine Kaposi's Sarcoma-Like Tumors Define New Animal Models for Studying and Targeting KSHV Oncogenesis and Replication [J].
Ashlock, Brittany M. ;
Ma, Qi ;
Issac, Biju ;
Mesri, Enrique A. .
PLOS ONE, 2014, 9 (01)
[4]   Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis [J].
Avey, Denis ;
Brewers, Brittany ;
Zhu, Fanxiu .
VIROLOGICA SINICA, 2015, 30 (02) :130-145
[5]  
Badiaga S, 1998, CLIN INFECT DIS, V27, P1558, DOI 10.1086/515047
[6]   Indirect Antitumor Effects of Mammalian Target of Rapamycin Inhibitors Against Kaposi Sarcoma in Transplant Patients [J].
Barozzi, Patrizia ;
Riva, Giovanni ;
Vallerini, Daniela ;
Bosco, Raffaella ;
Quadrelli, Chiara ;
Zanetti, Eleonora ;
Potenza, Leonardo ;
Forghieri, Fabio ;
Torelli, Giuseppe ;
Luppi, Mario .
TRANSPLANTATION, 2009, 88 (04) :597-598
[7]   Molecular mechanism for dimerization to regulate the catalytic activity of human cytomegalovirus protease [J].
Batra, R ;
Khayat, R ;
Tong, L .
NATURE STRUCTURAL BIOLOGY, 2001, 8 (09) :810-817
[8]   Regulation of KSHV Lytic Switch Protein Expression by a Virus-Encoded MicroRNA: An Evolutionary Adaptation that Fine-Tunes Lytic Reactivation [J].
Bellare, Priya ;
Ganem, Don .
CELL HOST & MICROBE, 2009, 6 (06) :570-575
[9]   Failure of cidofovir in HIV-associated multicentric Castleman disease [J].
Berezne, A ;
Agbalika, F ;
Oksenhendler, E .
BLOOD, 2004, 103 (11) :4368-4369
[10]   Design and synthesis of pyrrolidine-5,5′-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease.: 4.: Antiviral activity and plasma stability [J].
Borthwick, AD ;
Davies, DE ;
Ertl, PF ;
Exall, AM ;
Haley, TM ;
Hart, GJ ;
Jackson, DL ;
Parry, NR ;
Patikis, A ;
Trivedi, N ;
Weingarten, GG ;
Woolven, JM .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (21) :4428-4449